A Phase 3 Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Secutrelvir in Participants With COVID-19 Who Are at High Risk for Progression to Severe Disease

July 30, 2026August 7, 2026

A Phase 3 Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Secutrelvir in Participants With COVID-19 Who Are at High Risk for Progression to Severe Disease

Publication date: Jul 30, 2026

The primary purpose of this study is to evaluate the efficacy and safety of secutrelvir in symptomatic nonhospitalized adult and adolescent participants with COVID-19 who are at high risk for progression to severe disease.

Concepts	Keywords
Covid	COVID-19
Immunocompromised	S-892216
Influenza	SARS-CoV-2
Liver	Secutrelvir
Months

Semantics

Type	Source	Name
disease	MESH	COVID-19
disease	MESH	influenza
disease	MESH	cirrhosis
disease	MESH	ascites
disease	MESH	bleeding
disease	MESH	hepatic encephalopathy
disease	MESH	Gilbert’s syndrome
disease	MESH	post-acute sequelae of COVID-19
drug	DRUGBANK	Ritonavir